flonoltinib 100mg

DRUG4 trials

Sponsors

Guizhou Bailing Group Pharmaceutical Co Ltd, Chengdu Zenitar Biomedical Technology Co., Ltd

Conditions

MF,PMF,PPV-MF,PET-MFMyelofibrosis，MFMyeloproliferative Neoplasm (MPN)Polycythemia Vera (PV)

Phase 1

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

WithdrawnNCT05115344

Guizhou Bailing Group Pharmaceutical Co LtdMyeloproliferative Neoplasm (MPN), Myelofibrosis，MF

Start: 2021-11-12End: 2023-02-28Updated: 2026-08-13

Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

CompletedNCT05153343

Chengdu Zenitar Biomedical Technology Co., LtdMyeloproliferative Neoplasm (MPN), Myelofibrosis，MF

Start: 2021-12-27End: 2025-03-19Updated: 2025-10-01

Phase 2

A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

Active, not recruitingNCT06457425

Chengdu Zenitar Biomedical Technology Co., LtdMF,PMF,PPV-MF,PET-MF

Start: 2024-05-06End: 2027-05-12Updated: 2026-08-12

Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

RecruitingNCT07232290

Chengdu Zenitar Biomedical Technology Co., LtdPolycythemia Vera (PV)

Start: 2025-09-23End: 2028-02-28Target: 60Updated: 2026-08-14

Related Papers

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Blood2025-11-03

First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis

Blood2024-11-05